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Abstract
Background:  A considerable proportion of patients suffer from depression following acute
myocardial infarction. Information regarding this prevalence in Indian patients and response to
treatment is lacking.
Method: Prevalence of major depression was studied in 50 consecutive in-patients with acute
myocardial infarction following DSM-IV criteria. In a comparative study outcome of treatment with
sertraline in terms of recovery from depression, change in Hamilton Depression Rating scale score
and occurrence of cardiac events were ascertained for a 6-month period, which were compared
with a group of patients who did not receive sertraline.
Results: Major depression was diagnosed in 34% of patients. Female patients were more affected
than the males. Hamilton Depression Rating scale scores gradually decreased in both the groups
over the study period; however it became significantly less for patients treated with sertraline.
Significantly more number of patients who received sertraline recovered from depression. There
were no dropouts due to non-response or side effects. Cardiac events were reported less in this
group than those who continued only cardiac treatment as usual.
Conclusion:  A considerable proportion of acute myocardial infarction patients have major
depression. Sertraline is efficacious and safe in these patients. Antidepressant treatment might be
associated with reduction of cardiac events.
Introduction
Sadness is often portrayed as a feeling of heaviness in the
chest or as 'broken heart' [1]; and the relation has been a
subject of both literature and science. Symptoms of
depression in patients with acute myocardial infarction
(AMI) have been reported from 8 – 45% [2], up to 65 per-
cent [3]. Prevalence of major depression range from 10 to
37.7% in various reports [3-8]. Prevalence rates of 30.9%,
37.7% and 37.2% during hospitalization, and 4 and 12
months later respectively have been reported [7]. There is
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no available data on this from Indian population. Preva-
lence from neighboring Asian country Pakistan suggest
symptoms of depression in 14%, and mixed anxiety and
depression symptoms in 18% of the patients following
AMI [9]. The prevalence figures of depression following
AMI are considerably higher than the general population.
The presence of depression confers significant risks for
additional cardiac morbidity and mortality in patients
with coronary heart disease [4]. It increases hospital
length of stay, procedures, readmission rates, and the cost
of medical care [10]. It is associated with an increased risk
of re-infarction [4]; and is known to be an independent
risk factor for death after AMI [11,12]. In addition, major
depression at the time of diagnostic coronary angiogra-
phies more than doubles the risk of a major cardiac event
within one year [13]. Depression, even after adjustment
for potential confounders has been associated with signif-
icant worsening of quality of life in cardiac patients [14].
It predicts slow recovery and a poor quality of life follow-
ing AMI [15].
In spite of the fact that depression is an independent risk
factor additional care is rarely taken of depressed acute
myocardial infarction patients largely due to a failure in
identification [11]. With above background, considering
the facts that there is paucity of Indian data on this sub-
ject, we studied the prevalence of depression in AMI in-
patients. We also tried to find out the effect of antidepres-
sant treatment on the cardiac events up to 6 months, in a
prospective study.
Methods
The study was conducted in the departments of Cardiol-
ogy and Psychiatry of S.C.B. Medical College, Cuttack.
Consecutive patients suffering from acute myocardial inf-
arction, admitted to the cardiology ward were included in
the study. Patients, who were recovering from by-pass sur-
gery; patients having history of depressive disorders
before the onset of cardiac problem, current substance
harmful use or dependence which could contribute to
mood status; and those who are already receiving psycho-
tropic medications, were excluded.
The patients were randomized as treatment as usual group
or intervention group before being evaluated. The process
followed a design where participants are randomized to
control or intervention before consent is sought [16]. The
randomization was done by the cardiologist and one psy-
chiatrist (GK), and the rater (PM) remained blind to the
status of the participants. Informed consent was obtained.
All patients were clinically evaluated and diagnosed
according to Diagnostic and Statistical Manual of Mental
Disorders-IV [17]. Hamilton rating scale for depression
[18] (HDRS) were administered to asses the degree of
depression in the depressed patients.
Socio-demographic information and risk factors (hyper-
tension, diabetes mellitus, dislipidaemia, history of smok-
ing and alcohol abuse, and family history of coronary
artery disease (CAD) were recorded.
All the patients who were diagnosed to have depression
and were in the intervention group were offered antide-
pressant treatment. They were prescribed only sertraline,
considering reports of its greater tolerability in cardiac
patients [19]. The dose of sertraline was titrated to a range
of 50 to 200 mg per day depending upon clinical evalua-
tion. Patients in 'treatment as usual' (TAU) group contin-
ued to receive cardiological treatment as required, but
they had no antidepressant or other psychotropic medica-
tion. Patients in this group, who received antidepressant
medication during the study from their cardiologists or
other sources, were excluded from the study with the last
observation carried forward. Neither group received psy-
chotherapeutic intervention for depression.
Table 1: Prevalence of depression in different socio-demographic and clinical groups
Sociodemographic and clinical variables Total (n = 50) With depression (n = 17) %
Gender Male 38 10 26.3
Female* 12 7 58.3
Habitat Rural 25 9 36.0
Urban 25 8 32.0
Economic Status Low 18 6 33.3
Middle 31 11 34.3
Upper 1 0 0.0
Clinical risks Hypertension 19 8 42.1
Diabetes mellitus 18 6 33.3
Family History of CAD 10 5 50.0
History of smoking 15 6 40.0
History of alcohol abuse 4 2 50.0
% within the variable, * chi square: 4.16; 1, p = 0.041Clinical Practice and Epidemiology in Mental Health 2005, 1:26 http://www.cpementalhealth.com/content/1/1/26
Page 3 of 5
(page number not for citation purposes)
HDRS was repeated every month for period of six months.
The remission was defined as a HDRS score of 7 or less
[20]. One of the psychiatrists (GK) monitored the antide-
pressant treatment and side effects. Cardiac status was
monitored by the cardiologist and the cardiological events
viz. recurrent angina, re-infarction, re-hospitalization,
heart failure, and death due to cardiac cause were
recorded. Analysis was intention to treat. The study was
approved by the ethical committee of Mental Health Insti-
tute, SCB Medical College, Cuttack.
Results
Fifty consecutive patients (38 males and 12 females) were
enrolled in the study. Depression was found in 17 (34%)
patients. Prevalence of depression in various clinical
groups is given in table one. Mean age of the whole sam-
ple was 58.1 ± 10.2; for those with depression it was 55.8
± 11.4; which was not significantly different from that
(59.2 ± 9.7) of non-depressed patients.
Prevalence of depression in many socio-demographic var-
iables and risk groups were comparable except that signif-
icantly more females were depressed than males. All were
married and living with their spouses. None had dislipi-
daemia.
Table 2 shows socio-demographic profile and clinical
characteristics in intervention group and treatment as
usual groups. The groups were comparable including
mean age (tau group: 56.8 ± 10.8 and intervention group:
55.2 ± 12.1) and the HDRS scores (tau 16.67 ± 7.06 and
intervention group 15.0 ± 5.33). In the associated risk fac-
tors both the groups were also comparable except that
45% patients in the intervention group receiving antide-
pressants had family history of CAD, compared to none in
the tau group.
It was observed that HDRS scores gradually decreased in
both the groups over the study period, however it
remained significantly (t: 3.09, df = 15, p = 0.007) more
for the tau group (12.0 ± 5.76) in comparison with inter-
vention group (4.82 ± 3.84). At the end of six months ten
(90.9%) patients in intervention group achieved remis-
sion compared to two (33.3%) of the tau group. The
number needed to treat was around 2 (1.74). There were
no dropouts due to non-response or side effects. Cardiac
events were around 2.8 times more in the tau group com-
pared to the intervention group.
Discussion
The focused objective of the study was to find out the
prevalence of depression in patients with acute myocar-
dial infarction in an Indian population where such data
are not available; and to compare the response to antide-
pressant treatment between those who received it and
those who continued treatment as usual without it.
There are a few limitations of the study which need to be
highlighted while discussing the results. The sample size
was small. Universe of the study was in-patients at the
time of inclusion, so the prevalence may not be generalis-
able to outpatients. Severity of cardiac status was not
obtained in a structured way. Patients undergoing angiog-
raphy have been reported to be a specific risk group how-
ever that information was not noted. Other factors
contributing or related to depression for example psycho-
social issues and family history of depression were not
studied.
The prevalence of depression in patients with acute myo-
cardial infarction as observed in the index study (34%) is
comparable to that reported elsewhere [3-8]. One of the
many reasons for the variability in the prevalence could be
the different methodologies and diagnostic approach. It
Table 2: Comparison of Patient Characteristics in Intervention and TAU Group
Sociodemographic and clinical variables TAU (n = 6) Intervention (n = 11)
n%n%
Gender Male 4 66.7 6 45.5
Female 2 33.3 5 54.5
Habitat Rural 5 83.3 4 36.4
Urban 1 16.7 7 63.6
Economic Status Low 3 50.0 3 27.3
Middle 3 50.0 8 72.7
Clinical risks Hypertension 4 66.7 4 36.4
DM 1 16.7 5 45.5
Family History of 
CAD*
0 0.0 5 45.5
History of smoking 3 50.0 3 27.3
History of alcohol 
abuse
11 6 . 7 1 9 . 1
% within the treatment group; * Chi square: 3.86, df = 1, p = 0.049Clinical Practice and Epidemiology in Mental Health 2005, 1:26 http://www.cpementalhealth.com/content/1/1/26
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may be highlighted that sample of the index study were
in-patients recovering from acute myocardial infarction
who did not have past history of depression, or current
substance use that can influence mood. This suggests that
the prevalence rate is more closely related to AMI. There
was no difference in age, rural or urban habitat, socioeco-
nomic status, associated risk factors amongst the
depressed and non-depressed. Significantly more females
were depressed than males; which reaffirms their greater
vulnerability for depression.
Antidepressant treatment group and tau group were com-
parable considering age, gender and other socio-demo-
graphic variables studied. Sertraline has been found to be
cost effective strategy in this group of patients [21] making
it more relevant to choose. At the end of six months the
outcome regarding the remission of depression was signif-
icantly different between the two groups. Group HDRS
mean, which was comparable at the baseline, was signifi-
cantly less in the intervention group. In addition there
were no dropouts. Sertraline treatment was efficacious
and well tolerated similar to reported results [19].
It is known that presence of depression confers significant
risks for additional cardiac morbidity and mortality in
patients with CAD [1,4,22]. It is associated with an
increased risk of re-infarction and mortality following
acute infarction [4]. In the index study frequency of cardi-
ological events of both groups was considerably different
during the six-month study period; the group receiving
treatment had much less cardiological events. Treatment
of depression and reduction in cardiac morbidity might
be connected, and if this is convincingly proven, it would
establish a therapeutic advance in this group of patients
[23].
Conclusion
Prevalence of depression in myocardial infarction patients
being treated in the hospital was found to be 34%. Female
patients were more affected than the males. Sertraline was
safe and efficacious in AMI patients with depression. Less
number of cardiac events was reported in depressed
patients who received antidepressant treatment during the
six-month study period.
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